TWI708618B - Oral composition - Google Patents

Oral composition Download PDF

Info

Publication number
TWI708618B
TWI708618B TW104109233A TW104109233A TWI708618B TW I708618 B TWI708618 B TW I708618B TW 104109233 A TW104109233 A TW 104109233A TW 104109233 A TW104109233 A TW 104109233A TW I708618 B TWI708618 B TW I708618B
Authority
TW
Taiwan
Prior art keywords
soup
water
paiyusan
extract
cellulose
Prior art date
Application number
TW104109233A
Other languages
Chinese (zh)
Other versions
TW201620507A (en
Inventor
早坂奈美
Original Assignee
日商小林製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商小林製藥股份有限公司 filed Critical 日商小林製藥股份有限公司
Publication of TW201620507A publication Critical patent/TW201620507A/en
Application granted granted Critical
Publication of TWI708618B publication Critical patent/TWI708618B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/346Platycodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

本發明之目的在於提供一種排膿散及湯萃取物之吸濕性經抑制之使用性良好且為高品質之固體形狀之經口組合物等。 The object of the present invention is to provide an oral composition with high-quality solid shape and high-quality solid shape with suppressed hygroscopicity of Paiyu powder and soup extract.

一種固體形狀之經口組合物,其含有排膿散及湯萃取物與水溶性纖維素衍生物,且將排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物為1~20重量份。 An oral composition in a solid shape, which contains Papusan and soup extracts and water-soluble cellulose derivatives, and the blending ratio (dry weight ratio) of Papusan and soup extracts and water-soluble cellulose derivatives Calculated as the content of dry extract of Paiyusan and soup, the water-soluble cellulose derivative is 1-20 parts by weight relative to 100 parts by weight of Paiyusan and soup extract.

Description

經口組合物 Oral composition

本發明係關於一種以特定之調配比含有排膿散及湯萃取物與水溶性纖維素衍生物之固體形狀之經口組合物。 The present invention relates to an oral composition in a solid shape containing Papusan and soup extracts and water-soluble cellulose derivatives in a specific mixing ratio.

排膿散及湯萃取物由於吸濕性較高,故而含有排膿散及湯萃取物之製品存在製品黏膩或製品彼此黏連等製品之使用性或品質易變差之問題。又,如此,排膿散及湯萃取物由於吸濕性較高,故而亦有容易產生因吸濕而導致之變色,於外觀上產生不快感等品質價值明顯降低之問題。又,於製造含有排膿散及湯萃取物之製品時,由於排膿散及湯萃取物之較高之吸濕性,故而有良率變差之問題。 Paiyusan and soup extracts are highly hygroscopic, so products containing Paiyusan and soup extracts have problems such as stickiness of the products or adhesion of the products to each other, and the usability or quality of the products tends to deteriorate. In addition, because of the high hygroscopicity of Paiyusan and soup extracts, they are also prone to discoloration due to moisture absorption, causing unpleasantness in appearance, and other quality values are significantly reduced. In addition, when manufacturing products containing Paiyusan and soup extract, due to the higher hygroscopicity of Paiyusan and soup extract, there is a problem of poor yield.

另一方面,關於先前之各種製品,為了提昇製品本身之使用或製造中之使用性,例如使用澱粉等添加劑(非專利文獻1)。然而,於此種情形時,製品中之有效成分以外之添加劑等之調配比率變高,製品本身之體積變大,又,為了攝取所需量之有效成分而亦會產生必須服用大量製品之不良情況等。 On the other hand, with regard to various previous products, in order to improve the use of the product itself or the usability in manufacturing, for example, additives such as starch are used (Non-Patent Document 1). However, in this case, the blending ratio of additives other than the effective ingredients in the product becomes higher, and the volume of the product itself becomes larger. In addition, in order to take in the required amount of the effective ingredients, it also causes the disadvantage of having to take a large number of products. Situation etc.

根據該等情況,重要的是提供一種抑制排膿散及湯萃取物之較高之吸濕性、使用性更良好、且為高品質之製品,又,亦重要的是提昇製造時之良率。 According to these circumstances, it is important to provide a product with higher hygroscopicity, better usability, and high-quality products that inhibit Paiyusan and soup extracts, and it is also important to improve the yield during manufacturing. .

[先前技術文獻] [Prior Technical Literature] [非專利文獻] [Non-Patent Literature]

[非專利文獻1]日本醫藥品添加劑協會編,醫藥品添加物辭典 2007,藥事日報社,2009年11月6日發行 [Non-Patent Document 1] Edited by Japan Pharmaceutical Additives Association, Dictionary of Pharmaceutical Additives 2007, Yaoji Daily, published on November 6, 2009

本發明之目的在於提供一種排膿散及湯萃取物之吸濕性經抑制之使用性良好且為高品質之固體形狀之經口組合物。又,本發明之目的在於提供一種固體形狀之經口組合物中之排膿散及湯萃取物之吸濕抑制方法等。 The purpose of the present invention is to provide an oral composition with high-quality solid shape and good hygroscopicity of Paiyu powder and soup extracts. In addition, the object of the present invention is to provide a method for inhibiting moisture absorption of Pyosan powder and soup extract in a solid oral composition.

本發明者為了解決上述問題而進行反覆努力研究,結果意外地發現藉由使用吸濕性較高之水溶性纖維素衍生物,可抑制排膿散及湯萃取物之吸濕性。本發明係基於該見解進行進一步研究結果完成者,係如下所述者。 In order to solve the above-mentioned problems, the inventors have made repeated efforts and studies. As a result, they have unexpectedly discovered that the use of a water-soluble cellulose derivative with high hygroscopicity can inhibit the hygroscopicity of Paiyusan and soup extracts. The present invention is the result of further research based on this knowledge, and is as follows.

(1)固體形狀之經口組合物(1) Oral composition in solid form

項1-1.一種固體形狀之經口組合物,其含有排膿散及湯萃取物與水溶性纖維素衍生物,且將排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物為1~20重量份,較佳為3~20重量份。 Item 1-1. An oral composition in a solid form, which contains Papyosans and soup extracts and water-soluble cellulose derivatives, and the mixing ratio of Papyosans and soup extracts and water-soluble cellulose derivatives (Dry weight ratio) Converted to the dry extract content of Paiyusan and soup, relative to 100 parts by weight of Paiyusan and soup extract, the water-soluble cellulose derivative is 1-20 parts by weight, preferably 3-20 parts by weight Parts by weight.

項1-2.如項1-1記載之經口組合物,其中水溶性纖維素衍生物係選自由羧烷基纖維素、羥烷基纖維素、烷基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯、羥丙基甲基纖維素乙酸琥珀酸酯及其等之鹽所組成之群中之至少1種。 Item 1-2. The oral composition according to Item 1-1, wherein the water-soluble cellulose derivative is selected from carboxyalkyl cellulose, hydroxyalkyl cellulose, alkyl cellulose, and hydroxypropyl methyl cellulose At least one of the group consisting of phthalate, hydroxypropyl methyl cellulose acetate succinate and its salts.

項1-3.如項1-1或1-2記載之經口組合物,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素、羥乙基纖維素、羥甲基纖維素、羥乙基甲基纖維素、羥丙基甲基纖維素、甲基纖維素及其等之鹽所組成之群中之至少1種。 Item 1-3. The oral composition according to Item 1-1 or 1-2, wherein the water-soluble cellulose derivative is selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxy At least one of the group consisting of methyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose and their salts.

項1-4.如項1-1至1-3中任一項記載之經口組合物,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素及其等之鹽所組成之群中之至少1種。 Item 1-4. The oral composition according to any one of items 1-1 to 1-3, wherein the water-soluble cellulose derivative is selected from carboxymethyl cellulose, hydroxypropyl cellulose and the like At least one of the group of salt.

項1-5.如項1-1至1-4中任一項記載之經口組合物,其中經口組合物中之排膿散及湯萃取物為5~90重量%。 Item 1-5. The oral composition according to any one of Items 1-1 to 1-4, wherein the Paiyusan and the soup extract in the oral composition are 5 to 90% by weight.

項1-6.如項1-1至1-5中任一項記載之經口組合物,其中經口組合物中之水溶性纖維素衍生物為0.05~18重量%。 Item 1-6. The oral composition according to any one of Items 1-1 to 1-5, wherein the water-soluble cellulose derivative in the oral composition is 0.05 to 18% by weight.

項1-7.如項1-1至1-6中任一項記載之經口組合物,其為錠劑之形態。 Item 1-7. The oral composition according to any one of Items 1-1 to 1-6, which is in the form of a tablet.

項1-8.如項1-1至1-7中任一項記載之經口組合物,其進而含有矽酸類。 Item 1-8. The oral composition according to any one of Items 1-1 to 1-7, which further contains silicic acid.

(2)排膿散及湯萃取物之吸濕抑制方法(2) Methods of inhibiting moisture absorption of Paiyusan and soup extract

項2-1.一種排膿散及湯萃取物之吸濕抑制方法,其特徵在於:於固體形狀之經口組合物中,將排膿散及湯萃取物與水溶性纖維素衍生物以排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)計換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,併用水溶性纖維素衍生物1~20重量份、較佳為3~20重量份。 Item 2-1. A method for inhibiting moisture absorption of Paiyusan and soup extract, characterized in that: in a solid oral composition, Paiyusan and soup extract and water-soluble cellulose derivative are used to discharge The blending ratio (dry weight ratio) of the extracts of Pyosan and the soup and the water-soluble cellulose derivative is calculated as the content of dry extracts of the Pyosan and the soup, relative to 100 parts by weight of the extract of the Pyosan and the soup, and dissolved in water 1 to 20 parts by weight of the cellulose derivative, preferably 3 to 20 parts by weight.

項2-2.如項2-1記載之方法,其中水溶性纖維素衍生物係選自由羧烷基纖維素、羥烷基纖維素、烷基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯、羥丙基甲基纖維素乙酸琥珀酸酯及其等之鹽所組成之群中之至少1種。 Item 2-2. The method as described in Item 2-1, wherein the water-soluble cellulose derivative is selected from the group consisting of carboxyalkyl cellulose, hydroxyalkyl cellulose, alkyl cellulose, and hydroxypropyl methyl cellulose. At least one of the group consisting of diformate, hydroxypropyl methyl cellulose acetate succinate and their salts.

項2-3.如項2-1或2-2記載之方法,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素、羥乙基纖維素、羥甲基纖維素、羥乙基甲基纖維素、羥丙基甲基纖維素、甲基纖維素及其等之鹽所組成之群中之至少1種。 Item 2-3. The method according to Item 2-1 or 2-2, wherein the water-soluble cellulose derivative is selected from carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxymethyl cellulose At least one of the group consisting of vegetable, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose and their salts.

項2-4.如項2-1至2-3中任一項記載之方法,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素及其等之鹽所組成之群中之至少1種。 Item 2-4. The method according to any one of items 2-1 to 2-3, wherein the water-soluble cellulose derivative is selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose and salts thereof At least 1 species in the group.

項2-5.如項2-1至2-4中任一項記載之方法,其中經口組合物中之排膿散及湯萃取物為5~90重量%。 Item 2-5. The method according to any one of items 2-1 to 2-4, wherein the Paiyusan and the soup extract in the oral composition are 5 to 90% by weight.

項2-6.如項2-1至2-5中任一項記載之方法,其中經口組合物中之水溶性纖維素衍生物為0.05~18重量%。 Item 2-6. The method according to any one of items 2-1 to 2-5, wherein the water-soluble cellulose derivative in the oral composition is 0.05 to 18% by weight.

項2-7.如項2-1至2-6中任一項記載之方法,其中經口組合物為錠劑之形態。 Item 2-7. The method according to any one of items 2-1 to 2-6, wherein the oral composition is in the form of a lozenge.

項2-8.如項2-1至2-7中任一項記載之方法,其進而併用矽酸類。 Item 2-8. The method described in any one of items 2-1 to 2-7, which further uses silicic acid in combination.

(3)排膿散及湯萃取物之風味改善方法(3) Methods to improve the flavor of Paiyusan and soup extract

項3-1.一種排膿散及湯萃取物之風味改善方法,其特徵在於:於固體形狀之經口組合物中,將排膿散及湯萃取物與水溶性纖維素衍生物以排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)計換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,併用水溶性纖維素衍生物1~20重量份、較佳為3~20重量份。 Item 3-1. A method for improving the flavor of Paiyusan and soup extract, characterized in that: in a solid oral composition, Paiyusan and soup extract and a water-soluble cellulose derivative are used to drain pus The blending ratio (dry weight ratio) of the powder and soup extract and the water-soluble cellulose derivative is calculated as the dry extract content of Paiyu powder and soup, relative to 100 parts by weight of Paiyu powder and soup extract, and water-soluble The cellulose derivative is 1-20 parts by weight, preferably 3-20 parts by weight.

項3-2.如項3-1記載之方法,其中水溶性纖維素衍生物係選自由羧烷基纖維素、羥烷基纖維素、烷基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯、羥丙基甲基纖維素乙酸琥珀酸酯及其等之鹽所組成之群中之至少1種。 Item 3-2. The method according to Item 3-1, wherein the water-soluble cellulose derivative is selected from the group consisting of carboxyalkyl cellulose, hydroxyalkyl cellulose, alkyl cellulose, and hydroxypropyl methyl cellulose. At least one of the group consisting of diformate, hydroxypropyl methyl cellulose acetate succinate and their salts.

項3-3.如項3-1或3-2中記載之方法,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素、羥乙基纖維素、羥甲基纖維素、羥乙基甲基纖維素、羥丙基甲基纖維素、甲基纖維素及其等之鹽所組成之群中之至少1種。 Item 3-3. The method described in Item 3-1 or 3-2, wherein the water-soluble cellulose derivative is selected from carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxymethyl At least one of the group consisting of cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose and their salts.

項3-4.如項3-1至3-3中任一項記載之方法,其中水溶性纖維素衍 生物係選自由羧甲基纖維素、羥丙基纖維素及其等之鹽所組成之群中之至少1種。 Item 3-4. The method according to any one of Items 3-1 to 3-3, wherein the water-soluble cellulose derivative The biological system is at least one selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose, and salts thereof.

項3-5.如項3-1至3-4中任一項記載之方法,其中經口組合物中之排膿散及湯萃取物為5~90重量%。 Item 3-5. The method according to any one of items 3-1 to 3-4, wherein the Paiyusan and the soup extract in the oral composition are 5 to 90% by weight.

項3-6.如項3-1至3-5中任一項記載之方法,其中經口組合物中之水溶性纖維素衍生物為0.05~18重量%。 Item 3-6. The method according to any one of Items 3-1 to 3-5, wherein the water-soluble cellulose derivative in the oral composition is 0.05 to 18% by weight.

項3-7.如項3-1至3-6中任一項記載之方法,其中經口組合物為錠劑之形態。 Item 3-7. The method according to any one of Items 3-1 to 3-6, wherein the oral composition is in the form of a lozenge.

項3-8.如項3-1至3-7中任一項記載之方法,其進而併用矽酸類。 Item 3-8. The method described in any one of items 3-1 to 3-7, which further uses silicic acid in combination.

根據本發明,可獲得可抑制排膿散及湯萃取物之吸濕性、雖然含有排膿散及湯萃取物但使用性良好、且為高品質之固體形狀之經口組合物。又,根據本發明,亦可顯著地抑制固體形狀之經口組合物之變色。又,根據本發明,儘管使用排膿散及湯萃取物,但可提昇製造時之良率。 According to the present invention, it is possible to obtain an oral composition that can inhibit the hygroscopicity of Paiyusan and soup extract, has good usability, and is in a high-quality solid form although it contains Paiyusan and soup extract. Furthermore, according to the present invention, the discoloration of solid oral compositions can also be significantly suppressed. In addition, according to the present invention, even though Paiyu powder and soup extract are used, the yield during manufacturing can be improved.

又,根據本發明,儘管與排膿散及湯萃取物併用之水溶性纖維素衍生物之比率相對較低,但可有效地抑制排膿散及湯萃取物之吸濕性。 Furthermore, according to the present invention, although the ratio of the water-soluble cellulose derivative used in combination with Paiyusan and soup extract is relatively low, the hygroscopicity of Paiyusan and soup extract can be effectively inhibited.

進而,根據本發明,可改善排膿散及湯萃取物特有之苦味或澀味等令人感到不快之風味,可減輕服用者之痛苦。 Furthermore, according to the present invention, unpleasant flavors such as bitterness or astringency peculiar to Paiyusan and soup extracts can be improved, and the pain of the user can be alleviated.

以下,對本發明進行具體說明。 Hereinafter, the present invention will be specifically described.

(I)固體形狀之經口組合物(I) Oral composition in solid form

本發明之固體形狀之經口組合物之特徵在於:其含有排膿散及 湯萃取物與水溶性纖維素衍生物,且將排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物為1~20重量份。 The oral composition in solid shape of the present invention is characterized in that it contains Papu powder and Soup extract and water-soluble cellulose derivative, and the blending ratio (dry weight ratio) of Paiyusan and soup extract and water-soluble cellulose derivative is converted into Paiyusan and the dry extract content of soup, relative to 100 parts by weight of Paiyusan and soup extract, and 1-20 parts by weight of water-soluble cellulose derivatives.

排膿散及湯萃取物Paiyu San and soup extract

於本發明中,作為排膿散及湯之植物原料,具體而言,例如為枳實(Citrus aurantium L.var.daidai Makino、Citrus aurantium Linne、Citrus natsudaidai Hayata)、甘草(Glycyrrhiza uralensis Fischer、Glycyrrhiza glabra Linne)、生薑(Zingiber officinale Roscoe)、芍藥(Paeonia lactiflora Pallas)、大棗(Zizyphus jujuba Miller var.inermis Rehder)、桔梗(Platycodon grandiflorum A.De Candolle)。該等植物原料係依據日本藥典而規定使用部位。 In the present invention, as the plant raw materials for Paipu powder and soup, specifically, for example, Citrus aurantium (Citrus aurantium L.var.daidai Makino, Citrus aurantium Linne, Citrus natsudai dai Hayata), licorice (Glycyrrhiza dai Linne), ginger (Zingiber officinale Roscoe), peony (Paeonia lactiflora Pallas), jujube (Zizyphus jujuba Miller var. inermis Rehder), platycodon grandiflorum (Platycodon grandiflorum A. De Candolle). These plant raw materials are used according to the Japanese Pharmacopoeia.

於本發明中可使用之排膿散及湯之製備可依據一般用中藥製劑承認基準、「新 一般用中藥配方入門」(合田幸廣、袴塚高志監修,日本中藥生藥製劑協會編集,Jiho公司發行)、「修訂 一般用中藥配方入門」(財團法人日本公定書協會監修,日本中藥生藥製劑協會編集,Jiho公司發行)等而進行。例如,只要依據一般用中藥製劑承認基準,則將其成分及分量設為枳實2~3(重量份,以下相同)、甘草3、生薑0.5~1、芍藥3、大棗3~6、桔梗3~4,於使用老薑代替生薑之情形時,原則上使用老薑2~3。 The preparation of Paiyusan and soup that can be used in the present invention can be based on the approval criteria for general Chinese medicine preparations, "Introduction to New General Chinese Medicine Formulas" (supervised by Yukhiro Aida and Takashi Hakamazuka, compiled by the Japan Traditional Chinese Medicine Association, issued by Jiho) , "Introduction to the Revision of General Chinese Medicine Formula" (supervised by the Japan Association of Gazetteers, compiled by the Japan Chinese Medicine Biopharmaceutical Association, issued by Jiho), etc. For example, as long as it is based on the approval criteria for general Chinese medicine preparations, the ingredients and weights should be set as citrus aurantium 2~3 (weight parts, the same below), licorice 3, ginger 0.5~1, peony 3, jujube 3~6, Platycodon 3~4, when using old ginger instead of ginger, use old ginger 2~3 in principle.

再者,根據書籍,亦有上述成分或成分比多少不同者(於上述分量中,將大棗設為6,將桔梗設為3者(精選百八方 臨床中藥研究會發行))等,又,亦可使用上述分量中將枳實設為6、生薑設為3、芍藥設為6者,只要根據書籍等而適當使用即可。 In addition, according to books, there are some different ingredients or ratios of the above ingredients (in the above weight, jujube is set to 6 and platycodon is set to 3 (issued by the Selected Baibafang Clinical Chinese Medicine Research Association)), etc. Among the above-mentioned components, those with Citrus aurantium as 6, ginger as 3, and peony as 6 can also be used as long as they are appropriately used according to books and the like.

於本發明中,作為排膿散及湯萃取物,只要為可自排膿散及湯所獲得之萃取物則無限制。於本發明中所使用之排膿散及湯萃取物係 如由中藥生藥調查會制定之「中藥製劑之基本使用方針」所規定般,包含目前繁用之中藥關係之書籍中所記載之可自中藥配方(生藥調配物)獲得之萃取物。 In the present invention, as the extracts of Paiyusan and soup, there is no limitation as long as it is an extract obtained from Paiyusan and soup. Paiyu powder and soup extract used in the present invention As stipulated in the "Basic Usage Guidelines for Chinese Medicine Preparations" formulated by the Chinese Medicines Investigation Association, it contains the extracts that can be obtained from Chinese herbal formulas (prescriptions of herbal medicines) described in books about the relationship between traditional Chinese medicines.

於本發明中,作為排膿散及湯萃取物之例,可列舉可自排膿散及湯獲得之萃取物,更具體而言,可例示使用水、乙醇等有機溶劑、該等之混合物等之類的萃取溶劑而自排膿散及湯萃取者。萃取順序並無限制,作為其一例,對構成排膿散及湯之生藥之混合物,使用約10~20倍量之萃取溶劑,於80~100℃左右之溫度下靜置1~3小時左右或攪拌萃取,視需要經由離心分離或過濾等而獲得萃取物。所獲得之萃取物可為液狀,亦可進行濃縮、稀釋或純化,可藉由噴霧乾燥處理或冷凍乾燥處理等公知方法加以乾燥,亦可視需要藉由於乾燥後粉碎而製成粉狀等,其形態只要根據使用態樣而適當決定即可,並無限制。就可進一步發揮出本發明之效果之觀點而言,於本發明中所使用之排膿散及湯萃取物之形態較佳為例示固體形狀,更佳為例示乾燥萃取物之形態。排膿散及湯萃取物亦可使用市售品。 In the present invention, examples of Paiyusan and soup extracts include extracts that can be obtained from Paiyusan and soup, and more specifically, the use of organic solvents such as water and ethanol, mixtures of these, etc. Such extraction solvents are extracted from Paiyu San and soup. The order of extraction is not limited. As an example, use 10-20 times the amount of extraction solvent for the mixture of crude drugs that constitute Paiyusan and soup, and let stand at 80-100℃ for about 1 to 3 hours or Stir and extract, and obtain the extract through centrifugal separation or filtration as needed. The obtained extract may be in liquid form, or it may be concentrated, diluted or purified. It may be dried by known methods such as spray drying treatment or freeze-drying treatment, or it may be powdered by pulverization after drying if necessary. The form is not limited as long as it is appropriately determined in accordance with the usage state. From the viewpoint of further exerting the effects of the present invention, the form of the Paiyusan and the soup extract used in the present invention is preferably an exemplified solid shape, and more preferably an exemplified dry extract. Commercial products can also be used for Paiyusan and soup extract.

水溶性纖維素衍生物Water-soluble cellulose derivatives

於本發明中,作為水溶性纖維素衍生物,只要可獲得本發明之效果則無限制。作為水溶性纖維素衍生物,可例示:羧甲基纖維素(CMC)等羧烷基纖維素;羥丙基纖維素(HPC)、羥乙基纖維素(HEC)、羥甲基纖維素(HMC)、羥乙基甲基纖維素(HEMC)、羥丙基甲基纖維素(HPMC)等羥烷基纖維素;甲基纖維素(MC)等烷基纖維素;羥丙基甲基纖維素鄰苯二甲酸酯(HPMCP)、羥丙基甲基纖維素乙酸琥珀酸酯(HPMCAS)、其等之鹽等。作為鹽,可例示鉀鹽、鈉鹽、鈣鹽等,較佳為例示鈉鹽、鈣鹽。 In the present invention, the water-soluble cellulose derivative is not limited as long as the effects of the present invention can be obtained. Examples of water-soluble cellulose derivatives include carboxyalkyl cellulose such as carboxymethyl cellulose (CMC); hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), and hydroxymethyl cellulose ( Hydroxyalkyl celluloses such as HMC), hydroxyethyl methyl cellulose (HEMC) and hydroxypropyl methyl cellulose (HPMC); alkyl celluloses such as methyl cellulose (MC); hydroxypropyl methyl cellulose Phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), their salts, etc. As the salt, potassium salt, sodium salt, calcium salt, etc. can be exemplified, and sodium salt and calcium salt are preferably exemplified.

作為水溶性纖維素衍生物,較佳為例示羧甲基纖維素、羥丙基纖維素、羥乙基纖維素、羥甲基纖維素、羥乙基甲基纖維素、羥丙基 甲基纖維素、甲基纖維素、其等之鹽等,更佳為例示羧甲基纖維素鈣、羧甲基纖維素鈉、羥丙基纖維素等,進而較佳為例示羧甲基纖維素鈣、羥丙基纖維素。 As water-soluble cellulose derivatives, preferably exemplified carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl Methyl cellulose, methyl cellulose, salts thereof, etc., more preferably exemplified carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, hydroxypropyl cellulose, etc., more preferably exemplified carboxymethyl cellulose Vegetarian calcium, hydroxypropyl cellulose.

該等可單獨使用1種,亦可將2種以上組合使用。 These may be used individually by 1 type, and may be used in combination of 2 or more types.

排膿散及湯萃取物及水溶性纖維素衍生物之含量The content of Paiyusan and soup extracts and water-soluble cellulose derivatives

於本發明中,將固體形狀之經口組合物中之排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物為1~20重量份,較佳為水溶性纖維素衍生物為3~20重量份,更佳為水溶性纖維素衍生物為5~12重量份。 In the present invention, the blending ratio (dry weight ratio) of Paiyusan and soup extract and water-soluble cellulose derivative in a solid oral composition is converted into the dry extract content of Paiyusan and soup, The water-soluble cellulose derivative is 1-20 parts by weight, preferably 3-20 parts by weight, and more preferably the water-soluble cellulose derivative, relative to 100 parts by weight of Paiyusan and soup extract. The content is 5-12 parts by weight.

於本發明中,固體形狀之經口組合物中之排膿散及湯萃取物之含量只要滿足上述調配比則無限制,可例示較佳為5~90重量%,更佳為10~90重量%,進而較佳為25~80重量%,尤佳為27.7~72.2重量%。 In the present invention, the content of Papusan and soup extract in the solid oral composition is not limited as long as it satisfies the above-mentioned blending ratio. It can be exemplified that it is preferably 5 to 90% by weight, more preferably 10 to 90% by weight. %, more preferably 25 to 80% by weight, particularly preferably 27.7 to 72.2% by weight.

於本發明中,固體形狀之組合物中之水溶性纖維素衍生物之含量只要滿足上述調配比則無限制,可例示較佳為0.05~18重量%,更佳為0.5~15重量%,進而較佳為0.7~13.3重量%,尤佳為2.8~13.3重量%。 In the present invention, the content of the water-soluble cellulose derivative in the solid-shaped composition is not limited as long as it satisfies the above-mentioned blending ratio. It can be exemplified that it is preferably 0.05-18% by weight, more preferably 0.5-15% by weight, and further It is preferably 0.7 to 13.3% by weight, and particularly preferably 2.8 to 13.3% by weight.

又,於本發明中,固體形狀之組合物中之排膿散及湯萃取物與水溶性纖維素衍生物之合計之含量亦只要滿足上述調配比則無限制,以排膿散及湯萃取物與水溶性纖維素衍生物之合計量計,可例示較佳為5.05~95重量%,更佳為30~85重量%,進而較佳為30.6~80重量%。 In addition, in the present invention, the total content of Papusan and soup extract and water-soluble cellulose derivative in the solid composition is also unlimited as long as the above-mentioned blending ratio is satisfied. The total amount with the water-soluble cellulose derivative is preferably 5.05 to 95% by weight, more preferably 30 to 85% by weight, and still more preferably 30.6 to 80% by weight.

其他成分Other ingredients

於本發明之固體形狀之經口組合物中,於不妨礙本發明之效果之範圍內進而視需要亦可含有可食性或藥學上所容許之賦形劑、結合 劑、崩解劑、潤滑劑、甜味劑、香料、色素、胺基酸、維生素類、有機酸鹽類等各種成分。其等係業者所公知,可適當選擇使用。 The solid-shaped oral composition of the present invention may contain edible or pharmaceutically acceptable excipients and combinations as needed within the range that does not hinder the effects of the present invention. Various ingredients such as agents, disintegrants, lubricants, sweeteners, flavors, colors, amino acids, vitamins, and organic acid salts. These are known by the industry and can be selected and used appropriately.

具體而言,作為該等之一例,可列舉:乳糖、白糖、糖醇、氯化鈉、葡萄糖、尿素、澱粉類、高嶺土、結晶纖維素、矽酸類(矽酸酐、矽酸鋁、矽酸鈣等)、磷酸鈣、碳酸鈣、糊精等賦形劑;聚乙烯吡咯啶酮、結晶纖維素、聚乙烯醇、聚乙二醇、糊精、明膠、阿拉伯膠等結合劑;澱粉類、纖維素衍生物、海藻酸鈉、瓊脂粉末、昆布糖粉末、碳酸氫鈉、碳酸鈣等崩解劑;純化滑石、硬脂酸、硬脂酸金屬鹽、蠟類、硼酸粉末、矽酸水合物、聚乙二醇等潤滑劑;甜菊、糖精、乙醯磺胺酸鉀、阿斯巴甜糖、蔗糖素等甜味劑等。 Specifically, as an example of these, lactose, sugar, sugar alcohol, sodium chloride, glucose, urea, starches, kaolin, crystalline cellulose, silicic acid (silicic anhydride, aluminum silicate, calcium silicate) Etc.), excipients such as calcium phosphate, calcium carbonate, dextrin; binders such as polyvinylpyrrolidone, crystalline cellulose, polyvinyl alcohol, polyethylene glycol, dextrin, gelatin, gum arabic, etc.; starches, fibers Disintegrants such as vegetarian derivatives, sodium alginate, agar powder, laminarum powder, sodium bicarbonate, calcium carbonate, etc.; purified talc, stearic acid, metal stearate, waxes, boric acid powder, silicic acid hydrate, Lubricants such as polyethylene glycol; sweeteners such as stevia, saccharin, potassium acetosulfamate, aspartame, sucralose, etc.

該等中之任意之成分只要為業者則可適當選擇,可含有單獨1種或組合2種以上。又,該成分之調配量為了適合於設為目標之形態或嗜好等,只要於不妨礙本發明之效果之範圍內適當調整即可。 Any of these components can be appropriately selected as long as they are a manufacturer, and they may be contained singly or in combination of two or more. In addition, the blending amount of the component may be appropriately adjusted within a range that does not hinder the effects of the present invention in order to be suitable for the target form or taste.

並非限制本發明,例如於本發明之固體形狀之經口組合物中進而含有矽酸類之情形時,只要可發揮出本發明之效果,則其調配量並無限制,例如將排膿散及湯萃取物與矽酸類之調配比(乾燥重量比)換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,矽酸類可例示10~80重量份,較佳為25~75重量份。又,於該情形時,同樣地並非限制本發明,又,只要可發揮出本發明之效果則無限制,於本發明中,固體形狀之組合物中之矽酸類之含量可例示10~30重量%,較佳為15~25重量%。 The present invention is not limited. For example, when the solid oral composition of the present invention further contains silicic acid, as long as the effect of the present invention can be exhibited, there is no limit to the amount of the compound, such as the pus powder and soup The blending ratio of extract and silicic acid (dry weight ratio) is converted into the content of dry extract of Paiyusan and soup. Compared with 100 weight parts of Paiyusan and soup extract, silicic acid can exemplify 10~80 parts by weight. Preferably it is 25 to 75 parts by weight. Also, in this case, the present invention is not limited in the same way, and there is no limitation as long as the effects of the present invention can be exerted. In the present invention, the content of silicic acid in the solid shape composition can be exemplified by 10 to 30 weight. %, preferably 15-25% by weight.

形態及製造方法等Form and manufacturing method, etc.

本發明之經口組合物只要為固體形狀,則其形態及大小等並無限制。作為本發明之經口組合物之形態,可例示散劑、細粒劑、顆粒劑、丸劑、錠劑、口含劑、塗佈劑等形態。就可進一步發揮出本發明之效果之方面而言,較佳可例示散劑、細粒劑、顆粒劑、丸劑、錠 劑、口含劑之形態,更佳可例示錠劑之形態。 As long as the oral composition of the present invention has a solid shape, its form, size, etc. are not limited. As the form of the oral composition of the present invention, there can be exemplified forms such as powders, fine granules, granules, pills, lozenges, oral preparations, and coatings. In terms of further exerting the effects of the present invention, powders, fine granules, granules, pills, tablets are preferably exemplified The form of the medicine and the oral medicine is more preferably the form of the tablet.

本發明之固體形狀之經口組合物可根據如下之業界之通常方法而製造:如上述般以排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)計換算為排膿散及湯之乾燥萃取物含量,以相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物成為1~20重量份之方式將排膿散及湯萃取物與水溶性纖維素衍生物,進而視需要與任意之成分根據公知之方法加以混合,進而視需要進行造粒等。又,固體形狀之經口組合物之上述各種形態亦可根據業界公知之方法而製造。關於該等情況,只要為業者則可容易地理解。並非加以限制,本發明之固體形狀之經口組合物係基於例如下述實施例而製造。 The solid oral composition of the present invention can be manufactured according to the following common methods in the industry: as described above, the formula ratio (dry weight ratio) of the puyu powder and the soup extract and the water-soluble cellulose derivative is calculated as The content of the dry extract of Paiyusan and soup is based on 100 parts by weight of Paiyusan and soup extract, and the water-soluble cellulose derivative becomes 1-20 parts by weight. The cellulose derivative is further mixed with optional components according to a known method as necessary, and granulated as necessary. In addition, the above-mentioned various forms of the oral composition in a solid shape can also be produced according to methods known in the industry. Regarding these situations, anyone in the business can easily understand. Without limitation, the solid oral composition of the present invention is manufactured based on, for example, the following examples.

本發明之固體形狀之經口組合物之大小或每天之攝取量亦可根據服用者之狀態或症狀之程度而適當變更,一名成人(體重60kg)每天之投與量換算為排膿散及湯之乾燥萃取物重量可例示通常為1~10g左右,較佳為1.5~8g左右,更佳為1.5~7g左右。又,本發明之固體形狀之經口組合物之服用次數亦無限制,通常一天服用1~3次。服用時間並無特別限定,較佳為進餐前或餐與餐之間。 The size or daily intake of the solid oral composition of the present invention can also be appropriately changed according to the state of the user or the degree of symptoms. The daily dose of an adult (weight 60kg) is converted into Papusan and The weight of the dry extract of the soup is usually about 1 to 10 g, preferably about 1.5 to 8 g, and more preferably about 1.5 to 7 g. In addition, there is no limit to the number of times of taking the solid oral composition of the present invention, and it is usually taken 1 to 3 times a day. The taking time is not particularly limited, and it is preferably before a meal or between meals.

如此,本發明之固體形狀之經口組合物係以上述特定之調配比含有排膿散及湯萃取物與水溶性纖維素衍生物者,可改善排膿散及湯萃取物容易吸濕、黏膩或黏連等使用不便、無法獲得高品質之固體形狀之經口組合物之不良情況。又,本發明之固體形狀之經口組合物亦可刻意地抑制其變色。 In this way, the oral composition of the present invention in a solid shape contains Pyongsan and soup extracts and water-soluble cellulose derivatives in the above-mentioned specific mixing ratio, which can improve Pyongsan and soup extracts to absorb moisture and stickiness. Greasy or sticky oral composition that is inconvenient to use and unable to obtain a high-quality solid shape oral composition. In addition, the solid oral composition of the present invention can also deliberately suppress its discoloration.

又,根據本發明之固體形狀之經口組合物,儘管使用排膿散及湯萃取物,但可提昇其製造時之良率,進而例如於將本發明之固體形狀之經口組合物製成錠劑形態之情形等時可提昇其打錠性。 Moreover, according to the oral composition of the present invention in a solid shape, even though the pus powder and soup extract are used, the yield rate during its manufacture can be improved. For example, the oral composition of the present invention can be made into a solid shape. The shape of the tablet can improve its tableting performance.

又,根據本發明,儘管水溶性纖維素衍生物之調配比較低,且水溶性纖維素衍生物係吸濕性較高之成分,但意外地是藉由將水溶性 纖維素衍生物應用於排膿散及湯萃取物,可有效地抑制排膿散及湯萃取物之吸濕性。因此,根據本發明,雖可有效地抑制排膿散及湯萃取物之吸濕性但仍可抑制組合物總體之總量,因此可抑制組合物本身之體積並且高效率地攝取所需量之排膿散及湯萃取物。 In addition, according to the present invention, although the formulation of water-soluble cellulose derivatives is relatively low and the water-soluble cellulose derivatives are components with higher hygroscopicity, it is unexpectedly Cellulose derivatives are used in Paiyusan and soup extracts, which can effectively inhibit the hygroscopicity of Paiyusan and soup extracts. Therefore, according to the present invention, although the hygroscopicity of Paiyusan and soup extracts can be effectively suppressed, the total amount of the composition can still be suppressed, so the volume of the composition itself can be suppressed and the required amount can be taken efficiently Paipu powder and soup extract.

進而,根據本發明,可改善排膿散及湯萃取物特有之苦味或澀味等難以服用之令人感到不快之風味,可減輕服用者之痛苦。 Furthermore, according to the present invention, it is possible to improve the unpleasant flavor that is difficult to take, such as the bitter or astringent peculiar to the extract of Paiyusan and the soup extract, and reduce the pain of the user.

如此,根據本發明,儘管含有排膿散及湯萃取物,但可獲得高品質之固體形狀之經口組合物。 Thus, according to the present invention, even though it contains Papusan and soup extract, a high-quality solid-shaped oral composition can be obtained.

(II)排膿散及湯萃取物之吸濕抑制方法及風味改善方法(II) Methods of inhibiting moisture absorption and improving flavor of Paiyusan and soup extract

如上所述,藉由以上述調配比將排膿散及湯萃取物與水溶性纖維素衍生物併用,可抑制排膿散及湯萃取物之吸濕。又,如上所述,藉由以述調配比將排膿散及湯萃取物與水溶性纖維素衍生物併用,可改善排膿散及湯萃取物之風味。根據該情況,本發明進而提供排膿散及湯萃取物之吸濕抑制方法,其特徵在於:於固體形狀之經口組合物中,將排膿散及湯萃取物與水溶性纖維素衍生物以排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)計換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,併用水溶性纖維素衍生物1~20重量份。又,本發明進而提供排膿散及湯萃取物之風味改善方法,其特徵在於:於固體形狀之經口組合物中,將排膿散及湯萃取物與水溶性纖維素衍生物以排膿散及湯萃取物與水溶性纖維素衍生物之調配比(乾燥重量比)計換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,併用水溶性纖維素衍生物1~20重量份。 As described above, by using the Paiyusan and the soup extract together with the water-soluble cellulose derivative in the above-mentioned mixing ratio, the moisture absorption of the Paiyusan and the soup extract can be suppressed. In addition, as described above, the flavor of Paiyusan and soup extract can be improved by using the combination of Paiyusan and soup extract with water-soluble cellulose derivatives. According to this situation, the present invention further provides a method for inhibiting moisture absorption of Paiyusan and soup extract, characterized in that: in a solid oral composition, Paiyusan and soup extract are combined with a water-soluble cellulose derivative Based on the blending ratio (dry weight ratio) of Paiyusan and soup extracts and water-soluble cellulose derivatives, converted to Paiyusan and soup dry extract content, relative to 100 parts by weight of Paiyusan and soup extracts, 1-20 parts by weight of water-soluble cellulose derivatives are used together. In addition, the present invention further provides a method for improving the flavor of Paiyu powder and soup extract, which is characterized in that: in a solid oral composition, Paiyu powder and soup extract and water-soluble cellulose derivatives are used to drain pus The blending ratio (dry weight ratio) of the powder and soup extract and the water-soluble cellulose derivative is calculated as the dry extract content of Paiyu powder and soup, relative to 100 parts by weight of Paiyu powder and soup extract, and water-soluble 1-20 parts by weight of cellulose derivatives.

關於該等方法中所使用之排膿散及湯萃取物、水溶性纖維素衍生物,又,固體形狀之經口組合物、其等之調配比等係與上述同樣地說明。 Regarding the Papyong powder, soup extract, and water-soluble cellulose derivative used in these methods, the solid oral composition, the blending ratio thereof, and the like are described in the same manner as above.

根據此種吸濕抑制方法,於固體形狀之經口組合物中,儘管使用排膿散及湯萃取物,但可抑制其吸濕性。又,根據此種風味改善方法,於固體形狀之經口組合物中,儘管使用排膿散及湯萃取物,但可改善其之風味。又,該等本發明亦可發揮出上述各種效果,對於提供雖然含有排膿散及湯萃取物但具有更高品質之固體形狀之經口組合物有用。 According to this method for inhibiting moisture absorption, in the oral composition in a solid form, although the Papusan and the soup extract are used, the moisture absorption can be inhibited. In addition, according to this flavor improvement method, in a solid oral composition, the flavor of the oral composition can be improved despite the use of Papu powder and soup extract. In addition, these present inventions can also exert the above-mentioned various effects, and are useful for providing oral compositions of higher quality solid shapes even though they contain Papusan and soup extracts.

[實施例] [Example]

以下,列舉實施例對本發明進行說明,但本發明並不限定於該等實施例。 Hereinafter, the present invention will be described with examples, but the present invention is not limited to these examples.

1.固體形狀之經口組合物之製造(實施例1~7)1. Production of solid oral composition (Examples 1~7)

根據下述表1所示之組成將各成分加以混合,而製作實施例1~7所示之經口組合物(粉體)。 Each component was mixed according to the composition shown in the following Table 1, and the oral composition (powder) shown in Examples 1-7 was produced.

對所獲得之實施例1~7之經口組合物評估耐吸濕性。具體而言,於將所獲得之各經口組合物於40℃、相對濕度60%之恆溫槽內靜置1.5小時後、以目視觀察乾燥度與色調變化,按以下4個等級進行評估,即,無變化(表中◎)、幾乎無變化(表中○)、稍有變化(表中△)、有變化(表中×)(n=5)。「無變化(◎)」表示最抑制吸濕,「有變化(×)」表示最吸濕。 The oral compositions of Examples 1 to 7 obtained were evaluated for moisture absorption resistance. Specifically, after each oral composition obtained was allowed to stand in a constant temperature bath at 40°C and a relative humidity of 60% for 1.5 hours, the dryness and hue changes were visually observed, and evaluated according to the following 4 levels, namely , No change (◎ in the table), almost no change (○ in the table), slight change (△ in the table), and change (× in the table) (n=5). "No change (◎)" means the most moisture absorption is suppressed, and "change (×)" means the most moisture absorption.

進而,對所獲得之實施例1~7之經口組合物評估風味(飲用容易性)。具體而言,請5位測試者將所獲得之各經口組合物0.5g含入口中,綜合苦味、澀味、生藥味、甜味等,按以下4個等級進行評估,即,易飲用:4分、稍易飲用:3分、稍難飲用:2分、難以飲用:1分,將總分13分以上設為表中◎、9~12分設為表中○、5~8分設為表中△、4分以下設為表中×。 Furthermore, the obtained oral compositions of Examples 1 to 7 were evaluated for flavor (ease of drinking). Specifically, 5 testers were asked to take 0.5 g of each oral composition obtained in their mouths, and evaluate the combination of bitterness, astringency, crude drug taste, sweetness, etc. according to the following 4 levels, namely, easy to drink: 4 points, slightly easy to drink: 3 points, slightly difficult to drink: 2 points, hard to drink: 1 point, set the total score above 13 points as ◎ in the table, 9-12 points as ○ in the table, 5-8 points △ in the table, 4 points or less are set as × in the table.

又,不使用水溶性纖維素衍生物,除此以外,與實施例1同樣地根據以下表1所示之組成,製作比較例1所示之經口組合物。對所獲得之比較例1之經口組合物同樣地評估耐吸濕性及風味。 In addition, except that the water-soluble cellulose derivative was not used, the oral composition shown in Comparative Example 1 was produced in the same manner as in Example 1 based on the composition shown in Table 1 below. The oral composition of Comparative Example 1 thus obtained was similarly evaluated for moisture absorption resistance and flavor.

Figure 104109233-A0202-12-0013-1
Figure 104109233-A0202-12-0013-1

*1 排膿散及湯(以乾燥重量換算(重量份)計為枳實6、桔梗3、芍藥6、生薑3、大棗3、甘草3)之乾燥萃取物;*2 商品名E.C.G-505 NICHIRIN股份有限公司製造;*3 商品名HPC 日本曹達股份有限公司製造;*4 商品名Kyoword 700 協和化學工業股份有限公司製造;*5 商品名Corn Starch 日本Corn Starch股份有限公司製造;*6 商品名植物性硬脂酸鎂 太平化學產業股份有限公司製造 *1 Paiyu San and Decoction (calculated as the dried extract of Citrus aurantium 6, Platycodon grandiflorum 3, Paeonia lactiflora 6, ginger 3, jujube 3, licorice 3) in dry weight conversion (parts by weight); *2 Trade name ECG- 505 manufactured by NICHIRIN Co., Ltd.; *3 brand name HPC manufactured by Japan Soda Co., Ltd.; *4 brand name Kyoword 700 manufactured by Kyowa Chemical Industry Co., Ltd.; *5 brand name Corn Starch manufactured by Corn Starch Co., Ltd.; *6 product Plant-based magnesium stearate manufactured by Taiping Chemical Industry Co., Ltd.

由表1明確,於相對於排膿散及湯萃取物100重量份使用1~20重量份之羧甲基纖維素鈣或羥丙基纖維素之情形時(實施例1~7),與不使用羧甲基纖維素鈣或羥丙基纖維素之比較例1相比,耐吸濕性提昇。 It is clear from Table 1 that when 1-20 parts by weight of carboxymethyl cellulose calcium or hydroxypropyl cellulose is used relative to 100 parts by weight of Paiyu powder and soup extract (Examples 1-7), the difference Compared with Comparative Example 1 using carboxymethyl cellulose calcium or hydroxypropyl cellulose, the moisture resistance is improved.

尤其是,儘管自先前起已清楚水溶性纖維素衍生物為吸濕性較高之成分,但如實施例1~7般,藉由對吸濕性較高之排膿散及湯萃取物使用吸濕性較高之水溶性纖維素衍生物,意外地抑制了排膿散及湯萃取物之耐吸濕性。又,同樣地藉由使用水溶性纖維素衍生物,可減輕排膿散及湯萃取物獨特之苦味或澀味等令人感到不快之風味,而成 為容易服用之風味。 In particular, although it has been clear that water-soluble cellulose derivatives are highly hygroscopic components, as in Examples 1 to 7, by using the highly hygroscopic Pyosan and soup extracts The water-soluble cellulose derivatives with high hygroscopicity unexpectedly inhibited the hygroscopic resistance of Paipusan and soup extracts. In addition, the use of water-soluble cellulose derivatives can reduce the unpleasant flavors such as the unique bitterness or astringency of the soup extract and the unique bitterness or astringency of the soup extract. The flavor is easy to consume.

又,由表1明確,儘管與排膿散及湯萃取物併用之水溶性纖維素衍生物之比率較低,有效地抑制了排膿散及湯萃取物之吸濕性。 In addition, it is clear from Table 1 that although the ratio of the water-soluble cellulose derivative used in combination with Paiyusan and soup extract is relatively low, it effectively inhibits the hygroscopicity of Paiyusan and soup extract.

2.固體形狀之經口組合物之製造(實施例8~15)2. Manufacturing of solid oral composition (Examples 8-15)

根據以下之表2所示之組成,將各成分加以混合,製作實施例8~15所示之經口組合物(錠劑)。更具體而言,將根據表2所示之組成而獲得之混合物以使每錠成為360mg、9.5mm

Figure 104109233-A0202-12-0014-8
之方式利用手動打錠機(SMP-3,理研精機股份有限公司製造)進行打錠後(打錠壓力20MPa),對耐吸濕性、風味與上述同樣地進行評估。又,進而根據打錠時之黏附(sticking)、裂錠(capping)等對打錠容易性(打錠性)按以下之3個等級進行評估,即,易打錠且無黏附或裂錠(表中+++)、易打錠且幾乎無黏附或裂錠(表中++)、產生黏附或裂錠而難以打錠(表中+)。 According to the composition shown in Table 2 below, the components were mixed to prepare the oral compositions (tablets) shown in Examples 8-15. More specifically, the mixture obtained according to the composition shown in Table 2 will be 360 mg, 9.5 mm per tablet
Figure 104109233-A0202-12-0014-8
The method uses a manual tableting machine (SMP-3, manufactured by Riken Seiki Co., Ltd.) to perform tableting (a tableting pressure of 20 MPa), and evaluate the moisture resistance and flavor in the same manner as above. Furthermore, according to sticking, capping, etc., the ease of ingot punching (ingot ability) was evaluated according to the following three levels, that is, easy to punch without sticking or cracking ( (+++ in the table), easy to strike with almost no sticking or cracking (++ in the table), sticking or cracking and difficult to strike (+ in the table).

又,不使用水溶性纖維素衍生物,除此以外,與實施例8同樣地根據以下之表2所示之組成,製作比較例2所示之經口組合物。對所獲得之比較例2之經口組合物亦同樣地評估耐吸濕性、風味及打錠性。 In addition, except that the water-soluble cellulose derivative was not used, the oral composition shown in Comparative Example 2 was produced in the same manner as in Example 8 based on the composition shown in Table 2 below. The obtained oral composition of Comparative Example 2 was also evaluated in the same manner for moisture absorption resistance, flavor, and tableting properties.

又,使用防風通聖散萃取物代替排膿散及湯萃取物,不使用水溶性纖維素衍生物,除此以外,與實施例11同樣地製作比較例3所示之經口組合物。又,使用防風通聖散萃取物代替排膿散及湯萃取物,除此以外,與實施例11同樣地,即,於比較例3中進而使用水溶性纖維素衍生物,除此以外,與比較例3同樣地製作比較例4所示之經口組合物。對所獲得之比較例3及4之經口組合物亦同樣地評估耐吸濕性、風味及打錠性。 In addition, the oral composition shown in Comparative Example 3 was produced in the same manner as in Example 11, except that the Fangfengtongshengsan extract was used instead of the Papusan and the soup extract, and the water-soluble cellulose derivative was not used. In addition, Fangfengtongshengsan extract was used instead of Paiyusan and soup extracts, except that the same was done as in Example 11, that is, in Comparative Example 3, a water-soluble cellulose derivative was further used. Comparative Example 3 Similarly, the oral composition shown in Comparative Example 4 was produced. The oral compositions of Comparative Examples 3 and 4 obtained were also evaluated for moisture resistance, flavor, and tableting properties in the same manner.

Figure 104109233-A0202-12-0015-3
Figure 104109233-A0202-12-0015-3

*1 排膿散及湯(以乾燥重量換算(重量份)計為枳實6、桔梗3、芍藥6、生薑3、大棗3、甘草3)之乾燥萃取物;*2 商品名E.C.G-505 NICHIRIN股份有限公司製造;*4 商品名Kyoword 700 協和化學工業股份有限公司製造;*5 商品名Corn Starch 日本Corn Starch股份有限公司製造;*6 商品名植物性硬脂酸鎂 太平化學產業股份有限公司製造。*7 防風通聖散(以乾燥重量換算(重量份)計為當歸1.2、芍藥1.2、川芎1.2、山梔子1.2、連翹1.2、薄荷1.2、生薑1.2、荊芥1.2、防風1.2、麻黃1.2、大黃1.5、芒硝1.5、白術2、桔梗2、黃芩2、甘草2、石膏2、滑石3)之乾燥萃取物 *1 Paiyu San and Decoction (calculated as the dried extract of Citrus aurantium 6, Platycodon grandiflorum 3, Paeonia lactiflora 6, ginger 3, jujube 3, licorice 3) in dry weight conversion (parts by weight); *2 Trade name ECG- 505 manufactured by NICHIRIN Co., Ltd.; *4 brand name Kyoword 700 manufactured by Kyowa Chemical Industry Co., Ltd.; *5 brand name Corn Starch manufactured by Japan Corn Starch Co., Ltd.; *6 brand name vegetable magnesium stearate Taiping Chemical Industry Co., Ltd. Company manufacture. *7 Fangfeng Tongsheng San (calculated as Angelica 1.2, Peony 1.2, Ligusticum chuanxiong 1.2, Gardenia jasminoides) 1.2, Forsythia 1.2, Mint 1.2, Ginger 1.2, Nepeta 1.2, Fangfeng 1.2, Ephedra 1.2, Da Yellow 1.5, Glauber's salt 1.5, Atractylodes 2, platycodon 2, scutellaria 2, licorice 2, gypsum 2, talc 3) dry extract

由表2明確,即便於設為錠劑之形態之情形時,於相對於排膿散及湯萃取物100重量份併用1~20重量份之羧甲基纖維素鈣之情形時(實施例8~15),與不使用羧甲基纖維素鈣之比較例2相比,耐吸濕性亦提昇。由該比較例2明瞭,於設為錠劑之形態之情形時,尤其是會因排膿散及湯萃取物而導致耐吸濕性變差,難以打錠等明顯之不良情況,排膿散及湯萃取物難以製成錠劑之形態,又,即便可製為錠劑,使用性亦較差,品質亦容易劣化。儘管如此,確認藉由將水溶性纖維素衍生物應用於排膿散及湯萃取物,儘管為錠劑之形態,但可提昇耐吸濕性,進而於風味或打錠性方面亦得以提昇。又,確認即便於設為錠劑之形態之情形時,儘管與排膿散及湯萃取物併用之水溶性纖維素衍生物之比率相對較低,但可有效地抑制排膿散及湯萃取物之吸濕性,可獲得所需之改善效果。 It is clear from Table 2 that even when it is in the form of a lozenge, when 1-20 parts by weight of carboxymethyl cellulose calcium is used with respect to 100 parts by weight of Paiyu powder and soup extract (Example 8 ~15) Compared with Comparative Example 2 which does not use carboxymethyl cellulose calcium, the moisture resistance is also improved. It is clear from this comparative example 2 that when it is set in the form of a lozenge, in particular, it will cause obvious disadvantages such as poor hygroscopicity due to Paiyu powder and soup extract, and difficulty in taking tablets, such as Paiyu powder and The soup extract is difficult to make into a tablet form, and even if it can be made into a tablet, the usability is poor and the quality is easily deteriorated. Nevertheless, it is confirmed that by applying water-soluble cellulose derivatives to Paiyusan and soup extracts, although they are in the form of tablets, they can improve the moisture resistance, and the flavor and tableting properties can also be improved. In addition, it was confirmed that even in the case of the tablet form, although the ratio of the water-soluble cellulose derivative used in combination with Paiyusan and soup extract is relatively low, it can effectively inhibit Paiyusan and soup extract The hygroscopicity can obtain the required improvement effect.

另一方面,關於使用防風通聖散萃取物代替排膿散及湯萃取物之比較例3及4,比較例3為不併用水溶性纖維素衍生物之例,比較例4為併用水溶性纖維素衍生物之例,由比較例3及4之結果明確,於使用防風通聖散萃取物之情形時,不論是否使用水溶性纖維素衍生物均未觀察到吸濕性之抑制效果,又,於風味或打錠性之方面亦未提昇。 On the other hand, regarding Comparative Examples 3 and 4 using Fangfengtongshengsan extract instead of Paiyusan and Tang extracts, Comparative Example 3 is an example where water-soluble cellulose derivatives are not used in combination, and Comparative Example 4 is a combination of water-soluble fiber For the example of vegetarian derivatives, it is clear from the results of Comparative Examples 3 and 4 that when the Fangfengtongshengsan extract is used, no inhibitory effect of hygroscopicity is observed regardless of whether water-soluble cellulose derivatives are used. There is no improvement in terms of flavor or tableting properties.

3.配方例3. Formulation example

根據以下之配方例與上述同樣地製作本發明之固體形狀之經口組合物。任一經口組合物均為耐吸濕性及風味優異者。 According to the following formulation examples, the solid oral composition of the present invention was produced in the same manner as described above. Any oral composition has excellent moisture absorption resistance and flavor.

‧散劑 ‧Powder

Figure 104109233-A0202-12-0017-6
Figure 104109233-A0202-12-0017-6

‧顆粒劑 ‧Granules

Figure 104109233-A0202-12-0017-7
Figure 104109233-A0202-12-0017-7

Claims (4)

一種固體形狀之經口組合物,其含有排膿散及湯萃取物與水溶性纖維素衍生物,排膿散及湯萃取物之含量為25~80重量%,且將排膿散及湯萃取物與水溶性纖維素衍生物之調配量之乾燥重量比換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,水溶性纖維素衍生物為5~20重量份;上述水溶性纖維素衍生物係選自由羧烷基纖維素、羥烷基纖維素、烷基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯、羥丙基甲基纖維素乙酸琥珀酸酯及其等之鹽所組成之群中之至少1種。 An oral composition in a solid shape, which contains Paiyu powder and soup extract and water-soluble cellulose derivatives, the content of Paiyu powder and soup extract is 25 to 80% by weight, and the Payu powder and soup are extracted The dry weight ratio of the blending amount of the water-soluble cellulose derivative is converted into the dry extract content of Paiyusan and soup, relative to 100 parts by weight of Paiyusan and soup extract, the water-soluble cellulose derivative is 5~ 20 parts by weight; the above-mentioned water-soluble cellulose derivatives are selected from carboxyalkyl cellulose, hydroxyalkyl cellulose, alkyl cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl At least one of the group consisting of cellulose acetate succinate and its salts. 如請求項1之經口組合物,其中水溶性纖維素衍生物係選自由羧甲基纖維素、羥丙基纖維素及其等之鹽所組成之群中之至少1種。 The oral composition of claim 1, wherein the water-soluble cellulose derivative is at least one selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose, and salts thereof. 如請求項1或2之經口組合物,其為錠劑之形態。 Such as the oral composition of claim 1 or 2, which is in the form of a lozenge. 一種排膿散及湯萃取物之吸濕抑制及/或風味改善方法,其特徵在於:於排膿散及湯萃取物之含量為25~80重量%之固體形狀之經口組合物中,將排膿散及湯萃取物與水溶性纖維素衍生物以排膿散及湯萃取物與水溶性纖維素衍生物之調配量之乾燥重量比計換算為排膿散及湯之乾燥萃取物含量,相對於排膿散及湯萃取物100重量份,併用水溶性纖維素衍生物5~20重量份;上述水溶性纖維素衍生物係選自由羧烷基纖維素、羥烷基纖維素、烷基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯、羥丙基甲基纖維素乙酸琥珀酸酯及其等之鹽所組成之群中之至少1種。 A method for inhibiting moisture absorption and/or flavor improvement of Paiyusan and soup extract, which is characterized in that: in a solid oral composition with a content of Paiyusan and soup extract of 25 to 80% by weight, Paiyusan and soup extract and water-soluble cellulose derivative are converted to the dry extract content of Paiyusan and soup based on the dry weight ratio of the blending amount of Paiyusan and soup extract and water-soluble cellulose derivative. 5-20 parts by weight of water-soluble cellulose derivatives are used in combination with 100 parts by weight of Paiyusan and soup extracts; the water-soluble cellulose derivatives are selected from carboxyalkyl cellulose, hydroxyalkyl cellulose, and alkyl At least one of the group consisting of cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate and their salts.
TW104109233A 2014-03-28 2015-03-23 Oral composition TWI708618B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014069993A JP6373616B2 (en) 2014-03-28 2014-03-28 Oral composition
JP2014-069993 2014-03-28

Publications (2)

Publication Number Publication Date
TW201620507A TW201620507A (en) 2016-06-16
TWI708618B true TWI708618B (en) 2020-11-01

Family

ID=54195648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104109233A TWI708618B (en) 2014-03-28 2015-03-23 Oral composition

Country Status (3)

Country Link
JP (1) JP6373616B2 (en)
TW (1) TWI708618B (en)
WO (1) WO2015147141A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6839546B2 (en) * 2017-01-23 2021-03-10 株式会社ファンケル Carrot powder-containing tablets
JP2018184387A (en) * 2017-04-26 2018-11-22 大正製薬株式会社 Solid composition
JP7235193B2 (en) * 2017-04-26 2023-03-08 大正製薬株式会社 solid composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013194036A (en) * 2012-03-22 2013-09-30 Kobayashi Pharmaceutical Co Ltd Pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656727B2 (en) * 1994-05-17 1997-09-24 財団法人工業技術研究院 Moisture-proof Chinese herbal granules
JP2001181192A (en) * 1999-12-24 2001-07-03 Alps Yakuhin Kogyo Kk Moisture-proof galenical extract
JP5648303B2 (en) * 2010-03-19 2015-01-07 味の素株式会社 Method for producing powder granulated product having moisture absorption and consolidation resistance and powder granulated product
JP6062168B2 (en) * 2011-07-01 2017-01-18 武田薬品工業株式会社 Formulation containing herbal medicine-derived component and method for producing the same
JP2014166994A (en) * 2013-02-04 2014-09-11 Rohto Pharmaceut Co Ltd Novel chinese medicine extract formulation
JP6086798B2 (en) * 2013-04-25 2017-03-01 小林製薬株式会社 Tablet manufacturing method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013194036A (en) * 2012-03-22 2013-09-30 Kobayashi Pharmaceutical Co Ltd Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"排膿散及湯萃取物錠", 網址:https://www.pmda.go.jp/PmdaSearch/otcSearch/, 2012年10月13日. *

Also Published As

Publication number Publication date
TW201620507A (en) 2016-06-16
JP2015189743A (en) 2015-11-02
JP6373616B2 (en) 2018-08-15
WO2015147141A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
TWI795462B (en) Pharmaceutical preparation excellent in light stability and dissolution property
CN107362194B (en) Compound celery seed and sophora flower bud extract and medical application thereof
TWI708618B (en) Oral composition
WO2010133015A1 (en) Pharmaceutical composition for treating depression and preparative method and use thereof
CN104523791B (en) A kind of fresh ginseng activity extract oral disintegrating tablet and preparation method thereof
CN106983787A (en) It is a kind of to have by composition of stasis of blood function and preparation method thereof
CN104918627B (en) Pharmaceutical composition having preventive or therapeutic effect on inflammatory bowel disease
KR101581347B1 (en) Solid oral formulation comprising viscous extract of Magnolia cortex
CN112294883B (en) Stomach-strengthening tablet medicinal preparation and preparation method thereof
CN106715452B (en) Compound KS513, compositions containing same and uses thereof
JP2019034920A (en) PDE5 activity inhibitor
EP3139907B1 (en) Fast dissolving granulate
CN111714539B (en) Liver-protecting composition and preparation method and application thereof
JP6981641B2 (en) PDE5 activity inhibitor
JP7296198B2 (en) Pharmaceutical composition
JP4818549B2 (en) Aldose reductase inhibitor
JP2011063546A (en) Pharmaceutical composition
JP7287587B1 (en) solid composition
CN109771477B (en) Chewable tablet containing honeysuckle flower and radix scutellariae and preparation method thereof
CN106860619A (en) A kind of Chinese medicine composition of clearing heat and detoxicating purging intense heat defaecation and preparation method thereof
CN108938785B (en) Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof
JP5610671B2 (en) Foutsutsu Seisaku formulation
JP2022161887A (en) Solid pharmaceutical composition
KR20180136592A (en) Composition for anticancer containing extract of Jeju camellia mistletoe
JP2023084101A (en) Solid preparation

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees